h1
navindexsubmissionagendafacultyproglakeregistrationnav
title
Continuing Medical Education

This activity is sponsored by the University of Cincinnati.

Accreditation Statement

The University of Cincinnati designates this educational activity for a maximum of 14.75 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credits commensurate with the extent of their  participation in the activity.The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Target Audience

The intended audience will consist of experts in the fields of Infectious Diseases and Hepatology and Liver Transplantation, students, trainees, young investigators, nurse practitioners and other clinicians, and those involved with drug development and approval.

Statement of Need / Program Overview

This activity will address the critical need for cross-disciplinary venues that focus on issues of liver disease in HIV-infected patients. It will bring together a group of national and international thought leaders to present current and relevant data that promotes an understanding of liver disease in patients with HIV infection. It will also provide an educational opportunity for young investigators to interact with leading authorities in the fields of HIV and liver disease in a focused and intimate setting.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Review the epidemiology of HIV infection and liver disease in co-infected patients
  • Discuss current treatment guidelines for the management of HIV-infected patients with HBV and HCV
  • Explain issues of aging of the liver and other organs in the setting of HIV
  • Explain the pathogenesis of liver injury & disease progression in patients infected with HIV
  • Describe the effect of alcohol on liver injury and ways to reduce harm from alcohol and other substances
  • Report on the drugs currently being used and to be used for treatment of viral hepatitis
  • Analyze the progression of decompensated liver and HCC and the role of liver transplantation in those with HIV and liver disease
  • Assess the risk of antiretroviral therapy (ART) injury in patients with ESLD
  • Summarize the psychiatric difficulties that can develop in HIV-infected patients with liver disease
  • Examine treatment outcomes in injection drug users co-infected with HIV and liver disease
  • Describe issues applicable to management of HBV and other liver disease resource limited areas
  • Recognize emerging virus infections including HDV & HEV as well as NAFLD/NASH

Disclosure of Conflicts of Interest

According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Sponsored by University of Cincinnati
mer

Important Dates:

Registration opens - May 21
Abstract Submission opens - TBD
Housing Deadline - July 25

Faculty
Chair                                  
Kenneth E. Sherman, MD, PhD
Director, Division of Digestive Diseases
University of Cincinnati College of Medicine
Cincinnati, Ohio

Organizing Committee 
Marion Peters, MD
Chief of Hepatology Research
University of California San Francisco
San Francisco, California  

David Thomas, MD, MPH
Chief, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland